Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Left Arrow
    Right Arrow

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes Insipidus (NDI). The genesis of this technology began with Drs. Jeff Sands and Janet Klein, recognized clinical and research leaders in kidney diseases. While NDI patients are now living longer lives with fewer cognitive deficits, the quality of their lives remains diminished. Drs. Sand and Klein were inve...
    NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes Insipidus (NDI). The genesis of this technology began with Drs. Jeff Sands and Janet Klein, recognized clinical and research leaders in kidney diseases. While NDI patients are now living longer lives with fewer cognitive deficits, the quality of their lives remains diminished. Drs. Sand and Klein were investigating the role of AMPK activators as a promising potential therapy to reduce urine volume in NDI patients.

    List your booth number for exhibitions, ask us

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.